-
1 Comment
ICS Global Limited is currently in a long term uptrend where the price is trading 9.2% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
ICS Global Limited's total revenue sank by 100.0% to $110 since the same quarter in the previous year.
Its net income has dropped by 12.5% to $728K since the same quarter in the previous year.
Finally, its free cash flow fell by 112.0% to $-135K since the same quarter in the previous year.
Based on the above factors, ICS Global Limited gets an overall score of 2/5.
| ISIN | AU000000ICS4 |
|---|---|
| Sector | Financial Services |
| Industry | Shell Companies |
| Exchange | AU |
| CurrencyCode | AUD |
| PE Ratio | 0.0 |
|---|---|
| Beta | 0.81 |
| Target Price | None |
| Dividend Yield | 0.0% |
| Market Cap | 23M |
ICS Global Limited does not have significant operations. Previously, it was engaged in the provision of medical billing services primarily in the United Kingdom. The company was incorporated in 1996 and is based in Sydney, Australia. As of February 28, 2023, ICS Global Limited was taken private.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ICS.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
